Version 1
: Received: 16 March 2020 / Approved: 17 March 2020 / Online: 17 March 2020 (09:17:53 CET)
How to cite:
Kearney, J. Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: A Review. Preprints2020, 2020030275 (doi: 10.20944/preprints202003.0275.v1).
Kearney, J. Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: A Review. Preprints 2020, 2020030275 (doi: 10.20944/preprints202003.0275.v1).
Cite as:
Kearney, J. Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: A Review. Preprints2020, 2020030275 (doi: 10.20944/preprints202003.0275.v1).
Kearney, J. Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: A Review. Preprints 2020, 2020030275 (doi: 10.20944/preprints202003.0275.v1).
Abstract
There is a long trail of research studies testing the in vitro and in vivo efficacy of chloroquine and its derivatives in treating and preventing infection by various coronavirus species. More recent findings have highlighted the possibility of treating patients infected with the 2019 novel coronavirus, SARS-CoV-2. This review describes the mechanism of coronavirus infection, the mechanism of action of chloroquine, and summarizes the available literature highlighting the efficacy of chloroquine as an anti-coronavirus agent. These findings should encourage the wider scientific community to conduct thorough research on the possible efficacy of chloroquine and its derivatives in treating and preventing SARS-CoV-2 infection.
Keywords
Antimalarial; Chemoprophylaxis; Chloroquine; Coronavirus; COVID-19; Global Health; Hydroxychloroquine; Public Health; SARS-CoV-2; Virus
Subject
MEDICINE & PHARMACOLOGY, General Medical Research
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The commenter has declared there is no conflict of interests.
Comment:
Several trials are beginning in the United States testing the post-exposure prophylaxis use of hydroxychloroquine. One trial at the University of Minnesota (https://med.umn.edu/news-events/covid-19-clinical-trial-launches-university-minnesota) and another at the University of Washington (https://newsroom.uw.edu/news/does-antimalarial-drug-prevent-covid-19-study-seeks-answers.
Commenter:
The commenter has declared there is no conflict of interests.
Commenter:
The commenter has declared there is no conflict of interests.
Commenter: John Kearney
The commenter has declared there is no conflict of interests.